Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
adult (3) 3
aged (3) 3
aged, 80 and over (3) 3
breast cancer (3) 3
care and treatment (3) 3
endocrine therapy (3) 3
erbb-2 protein (3) 3
female (3) 3
humans (3) 3
index medicus (3) 3
middle aged (3) 3
oncology (3) 3
palbociclib (3) 3
post-menopause (3) 3
postmenopausal women (3) 3
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
breast neoplasms - drug therapy (2) 2
breast neoplasms - pathology (2) 2
cdk inhibitor (2) 2
clinical trial (2) 2
clinical trials (2) 2
clinical-trials (2) 2
criteria (2) 2
double-blind (2) 2
hormone receptor-positive (2) 2
kaplan-meier estimate (2) 2
leukopenia (2) 2
mammography (2) 2
medicine & public health (2) 2
neutropenia (2) 2
population studies (2) 2
product development (2) 2
ribociclib (2) 2
survival (2) 2
toxicity (2) 2
abc 3 (1) 1
aged patients (1) 1
alopecia (1) 1
aminopyridines - administration & dosage (1) 1
aminopyridines - therapeutic use (1) 1
antibiotics, antineoplastic - adverse effects (1) 1
antibiotics, antineoplastic - therapeutic use (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
breast - pathology (1) 1
breast neoplasms - mortality (1) 1
cancer therapies (1) 1
carcinoma, ovarian epithelial (1) 1
cdk4/6 (1) 1
cells (1) 1
chemotherapy-induced febrile neutropenia - epidemiology (1) 1
chemotherapy-induced febrile neutropenia - etiology (1) 1
controlled-trial (1) 1
cyclin-dependent kinase 4 (1) 1
de novo advanced breast cancer (1) 1
diarrhea (1) 1
disease-free survival (1) 1
double-blind method (1) 1
doxorubicin - adverse effects (1) 1
doxorubicin - analogs & derivatives (1) 1
doxorubicin - therapeutic use (1) 1
drug administration schedule (1) 1
drug resistance, neoplasm (1) 1
elderly (1) 1
epidermal growth factor (1) 1
epothilones (1) 1
epothilones - adverse effects (1) 1
epothilones - therapeutic use (1) 1
estrogen (1) 1
fallopian tube neoplasms - drug therapy (1) 1
fatigue (1) 1
geriatrics (1) 1
guidelines (1) 1
health aspects (1) 1
hormon receptor positive (1) 1
hormones (1) 1
incidence (1) 1
international consensus guidelines (1) 1
kinases (1) 1
letrozole (1) 1
letrozole - therapeutic use (1) 1
leukopenia - chemically induced (1) 1
leukopenia - epidemiology (1) 1
mechanism (1) 1
medicine, general & internal (1) 1
metastases (1) 1
metastasis (1) 1
microtubule-stabilizing agents (1) 1
myelosuppression (1) 1
nausea (1) 1
neoplasm recurrence, local - drug therapy (1) 1
neoplasm recurrence, local - pathology (1) 1
neoplasm staging (1) 1
neoplasms, glandular and epithelial - drug therapy (1) 1
neoplasms, glandular and epithelial - pathology (1) 1
nitriles - administration & dosage (1) 1
older people (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
by Hortobagyi, Gabriel N and Stemmer, Salomon M and Burris, Howard A and Yap, Yoon-Sim and Sonke, Gabe S and Paluch-Shimon, Shani and Campone, Mario and Blackwell, Kimberly L and André, Fabrice and Winer, Eric P and Janni, Wolfgang and Verma, Sunil and Conte, Pierfranco and Arteaga, Carlos L and Cameron, David A and Petrakova, Katarina and Hart, Lowell L and Villanueva, Cristian and Chan, Arlene and Jakobsen, Erik and Nusch, Arnd and Burdaeva, Olga and Grischke, Eva-Maria and Alba, Emilio and Wist, Erik and Marschner, Norbert and Favret, Anne M and Yardley, Denise and Bachelot, Thomas and Tseng, Ling-Ming and Blau, Sibel and Xuan, Fengjuan and Souami, Farida and Miller, Michelle and Germa, Caroline and Hirawat, Samit and O’Shaughnessy, Joyce
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 18, pp. 1738 - 1748
In patients with advanced HR-positive, HER2-negative breast cancer, the addition of the cyclin-dependent kinase inhibitor ribociclib to letrozole was... 
CRITERIA | CONTROLLED-TRIAL | PALBOCICLIB | MEDICINE, GENERAL & INTERNAL | PLACEBO | CDK4/6 | CLINICAL-TRIALS | DOUBLE-BLIND | ESTROGEN | POSTMENOPAUSAL WOMEN | Aminopyridines - administration & dosage | Triazoles - administration & dosage | Double-Blind Method | Drug Administration Schedule | Receptors, Estrogen | Humans | Middle Aged | Kaplan-Meier Estimate | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Purines - administration & dosage | Breast Neoplasms - drug therapy | Nitriles - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Receptors, Progesterone | Aged, 80 and over | Adult | Female | Aged | Receptor, ErbB-2 | Neoplasm Staging | Letrozole | Care and treatment | Postmenopausal women | Breast cancer | Health aspects | Leukopenia | Estrogen | Endocrine therapy | Metastasis | Kinases | Cancer therapies | Survival | Patients | ErbB-2 protein | Cyclin-dependent kinase 4 | Post-menopause | Metastases | Proteins | Epidermal growth factor | Womens health | Myelosuppression | Neutropenia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer
by Nicoletta Colombo and Elzbieta Kutarska and Meletios Dimopoulos and Duk-Soo Bae and Izabella Rzepka-Gorska and Mariusz Bidzinski and Giovanni Scambia and Svend Aage Engelholm and Florence Joly and Dirk Weber and Mona El-Hashimy and Jingjin Li and Farida Souami and Patricia Wing and Silke Engelholm and Aristotelis Bamias and Peter Schwartz
Journal of Clinical Oncology, ISSN 0732-183X, 11/2012, Volume 30, Issue 31, pp. 3841 - 3847
Purpose This study compared the efficacy and safety of patupilone with those of pegylated liposomal doxorubicin (PLD) in patients with platinum-refractory or... 
MICROTUBULE-STABILIZING AGENTS | CELLS | MECHANISM | ONCOLOGY | CLINICAL-TRIALS | EPOTHILONES | TOPOTECAN | TUBULIN | Doxorubicin - therapeutic use | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antibiotics, Antineoplastic - adverse effects | Neoplasm Recurrence, Local - drug therapy | Polyethylene Glycols - adverse effects | Drug Resistance, Neoplasm | Antineoplastic Agents - therapeutic use | Epothilones - therapeutic use | Epothilones - adverse effects | Polyethylene Glycols - therapeutic use | Neoplasm Recurrence, Local - pathology | Peritoneal Neoplasms - drug therapy | Antineoplastic Agents - adverse effects | Doxorubicin - analogs & derivatives | Aged, 80 and over | Adult | Female | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Treatment Outcome | Antibiotics, Antineoplastic - therapeutic use | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Aged | Organoplatinum Compounds - therapeutic use | Doxorubicin - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial
by O’Shaughnessy, Joyce and O’Shaughnessy, Joyce and Petrakova, Katarina and Petrakova, Katarina and Sonke, Gabe S and Sonke, Gabe S and Conte, Pierfranco and Conte, Pierfranco and Arteaga, Carlos L and Arteaga, Carlos L and Cameron, David A and Cameron, David A and Hart, Lowell L and Hart, Lowell L and Villanueva, Cristian and Villanueva, Cristian and Jakobsen, Erik and Jakobsen, Erik and Beck, Joseph T and Beck, Joseph T and Lindquist, Deborah and Lindquist, Deborah and Souami, Farida and Souami, Farida and Mondal, Shoubhik and Mondal, Shoubhik and Germa, Caroline and Germa, Caroline and Hortobagyi, Gabriel N and Hortobagyi, Gabriel N
Breast Cancer Research and Treatment, ISSN 0167-6806, 2/2018, Volume 168, Issue 1, pp. 127 - 134
Determine the efficacy and safety of first-line ribociclib plus letrozole in patients with de novo advanced breast cancer.Postmenopausal women with HR+ , HER2−... 
CDK inhibitor | Medicine & Public Health | Ribociclib | Endocrine therapy | Oncology | Breast cancer | De novo advanced breast cancer | Hormone receptor-positive | PALBOCICLIB | ONCOLOGY | ABC 3 | DOUBLE-BLIND | TUMORS | INTERNATIONAL CONSENSUS GUIDELINES | Receptors, Estrogen - metabolism | Chemotherapy-Induced Febrile Neutropenia - etiology | Humans | Letrozole - therapeutic use | Middle Aged | Response Evaluation Criteria in Solid Tumors | Incidence | Receptors, Progesterone - metabolism | Aminopyridines - therapeutic use | Time Factors | Leukopenia - chemically induced | Aged, 80 and over | Postmenopause | Adult | Female | Purines - therapeutic use | Breast - pathology | Chemotherapy-Induced Febrile Neutropenia - epidemiology | Kaplan-Meier Estimate | Leukopenia - epidemiology | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Progression-Free Survival | Breast Neoplasms - mortality | Aged | Antimitotic agents | Care and treatment | Clinical trials | Postmenopausal women | Product development | Antineoplastic agents | Clinical Trial
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial
by Sonke, Gabe S and Sonke, Gabe S and Hart, Lowell L and Hart, Lowell L and Campone, Mario and Campone, Mario and Erdkamp, Frans and Erdkamp, Frans and Janni, Wolfgang and Janni, Wolfgang and Verma, Sunil and Verma, Sunil and Villanueva, Cristian and Villanueva, Cristian and Jakobsen, Erik and Jakobsen, Erik and Alba, Emilio and Alba, Emilio and Wist, Erik and Wist, Erik and Favret, Anne M and Favret, Anne M and Bachelot, Thomas and Bachelot, Thomas and Hegg, Roberto and Hegg, Roberto and Wheatley-Price, Paul and Wheatley-Price, Paul and Souami, Farida and Souami, Farida and Sutradhar, Santosh and Sutradhar, Santosh and Miller, Michelle and Miller, Michelle and Germa, Caroline and Germa, Caroline and Burris, Howard A and Burris, Howard A
Breast Cancer Research and Treatment, ISSN 0167-6806, 2/2018, Volume 167, Issue 3, pp. 659 - 669
Determine the efficacy and safety of first-line ribociclib plus letrozole in elderly patients with HR+, HER2− advanced breast cancer.668 postmenopausal women... 
CDK inhibitor | Medicine & Public Health | Ribociclib | Endocrine therapy | Oncology | Breast cancer | Elderly | Hormone receptor-positive | CRITERIA | PALBOCICLIB | ONCOLOGY | GUIDELINES | Antimitotic agents | Care and treatment | Clinical trials | Aged patients | Postmenopausal women | Product development | Hormones | Antineoplastic agents | Clinical Trial
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.